Intermittent Fasting Decouples GH Anabolism from Insulin Resistance via Hepatic IGF-1 Suppression in Somatopause

Yuki Dlamini (DPhil)· Mar 26, 2026

Mechanism: Intermittent fasting (IF) reduces hepatic IGF-1 levels, which then decreases mTORC1 activity in muscle, preventing IRS-1 serine phosphorylation and preserving insulin sensitivity. Readout: Readout: This allows GH to promote lean mass gains without increasing HOMA-IR, improving metabolic health.

Hypothesis

Intermittent fasting (IF) modulates hepatic IGF-1 production such that GH pulses during somatopause retain anabolic effects on lean mass while avoiding the insulin‑resistant state seen with continuous GH elevation.

Mechanistic rationale

Somatopause is driven by reduced GHRH and increased somatostatin tone, yielding low‑amplitude GH pulses 5.
GH stimulates hepatic IGF-1 synthesis; elevated IGF-1 activates PI3K/Akt/mTOR, promoting serine phosphorylation of IRS-1 and impairing insulin signaling 3.
IF lowers circulating IGF-1 through reduced nutrient‑sensing (↓ insulin, ↑ FGF21) and increased IGFBP-1, which sequesters IGF-1 and diminishes its receptor activation 1.
Lower IGF-1 reduces mTORC1 activity in muscle, decreasing IRS-1 serine phosphorylation and preserving insulin‑stimulated AKT activation, thus counteracting GH‑induced insulin resistance.
The resulting state preserves GH‑mediated lipolysis and protein synthesis without the metabolic maladaptation observed in GH replacement trials.

Testable predictions

In older adults, a 16:8 IF regimen combined with a GH secretagogue (e.g., oral ghrelin agonist) will increase lean‑mass gains comparable to GH secretagogue alone, but will produce significantly lower fasting insulin and HOMA‑IR 3.
Hepatic IGF-1 mRNA expression will be reduced after 4 weeks of IF, correlating with improvements in peripheral insulin sensitivity measured by hyperinsulinemic‑euglycemic clamp.
Subjects receiving GH secretagogue without IF will show elevated IGF-1 and increased serine‑307 phosphorylation of IRS-1 in skeletal muscle biopsies, whereas the IF group will not.

Falsifiability If IF fails to lower IGF-1 or does not ameliorate GH‑associated insulin resistance (i.e., HOMA‑IR remains unchanged or worsens relative to secretagogue alone), the hypothesis is refuted.

Broader implications This framework suggests that longevity‑promoting attenuated GH/IGF-1 signaling can be achieved pharmacologically not by blunt GH suppression but by timing nutrient intake to modulate hepatic IGF-1 bioavailability, thereby rescuing the anabolic promise of GH while preserving metabolic health.

Hypothesis

Mechanistic rationale

Somatopause is driven by reduced GHRH and increased somatostatin tone, yielding low‑amplitude GH pulses 5.

GH stimulates hepatic IGF-1 synthesis; elevated IGF-1 activates PI3K/Akt/mTOR, promoting serine phosphorylation of IRS-1 and impairing insulin signaling 3.

IF lowers circulating IGF-1 through reduced nutrient‑sensing (↓ insulin, ↑ FGF21) and increased IGFBP-1, which sequesters IGF-1 and diminishes its receptor activation 1.

Lower IGF-1 reduces mTORC1 activity in muscle, decreasing IRS-1 serine phosphorylation and preserving insulin‑stimulated AKT activation, thus counteracting GH‑induced insulin resistance.

The resulting state preserves GH‑mediated lipolysis and protein synthesis without the metabolic maladaptation observed in GH replacement trials.

Testable predictions

In older adults, a 16:8 IF regimen combined with a GH secretagogue (e.g., oral ghrelin agonist) will increase lean‑mass gains comparable to GH secretagogue alone, but will produce significantly lower fasting insulin and HOMA‑IR 3.

Hepatic IGF-1 mRNA expression will be reduced after 4 weeks of IF, correlating with improvements in peripheral insulin sensitivity measured by hyperinsulinemic‑euglycemic clamp.

Subjects receiving GH secretagogue without IF will show elevated IGF-1 and increased serine‑307 phosphorylation of IRS-1 in skeletal muscle biopsies, whereas the IF group will not.